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Abstract
Objective—The relationship between depression and estrogen withdrawal remains controversial.
The authors examined the effects of gonadotropin-releasing hormone agonist-induced ovarian
suppression on mood, sleep, sexual function, and nighttime hot flushes. They focused on whether
participating women experienced clinically significant depressive symptoms and whether specific
symptoms associated with hypogonadism (nighttime hot flushes and disturbed sleep) increased
susceptibility to depression.
Method—Participants were 72 healthy pre-menopausal women, ages 19–52 years, with no
current or past axis I psychiatric diagnosis or gynecological or other medical illness. After 2
months of baseline screening, women received monthly injections of leuprolide acetate (3.75 mg)
for 2–3 months. Outcomes were measured using the Beck Depression Inventory (BDI) and a daily
rating scale measuring the severity of several affective and behavioral symptoms. Data were
analyzed by repeated-measures analysis of variance using PROC MIXED (for mixed models).
Results—BDI scores ≥10 were reported in four of the 72 women (5.6%). Relative to baseline,
induced hypogonadism was associated with significantly decreased sexual interest, disturbed
sleep, and more severe nighttime hot flushes, but no significant change in any mood-related
symptom score. Hot flush severity was significantly correlated with disturbed sleep.
Conclusions—These data demonstrate that clinically significant depressive symptoms were rare
accompaniments of short-term estradiol withdrawal and induced hypogonadism in healthy
premenopausal women. Additionally, neither nighttime hot flushes nor disturbed sleep were
sufficient to cause depressive symptoms in hypogonadal women.
Community-based studies (1–6) have demonstrated an association between the menopause
transition or early postmenopause and a higher risk of both first-onset and recurrent
depression. These studies have reported a 1.5-to threefold greater risk of first-onset and
recurrent depression in women during the menopause transition compared with those who
are premenopausal. At the same time, these studies have also demonstrated that most women
experience no significant symptoms of depression during the menopause transition.
A history of depression, disturbing vasomotor symptoms, and negative life events have all
been suggested as potential contributors to depression risk during the menopause transition.
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Yet none of these factors uniformly accompanies depression or has been shown to be a
necessary antecedent for its development in menopausal women. Results from a small
longitudinal observational study (7) and a clinic-based cross-sectional study (8), moreover,
have suggested that depressions associated with menopause tend to cluster late in the
transition and in early postmenopause, which are characterized by estradiol withdrawal and
the recent onset of hypogonadism (9, 10). Clinic-based observational studies (7, 8) and some
treatment studies (11, 12) have implicated changes in hormonal events during the
menopause transition—in particular, estradiol withdrawal—in the onset of depression.
Finally, in at least five studies, which together include over 70 premenopausal women, a
greater-than-expected frequency of clinically significant mood symptoms was observed
when a gonadotropin-releasing hormone (GnRH) agonist was used to suppress ovarian
function (13–18).
While these results suggest an association between declining or suppressed ovarian estradiol
secretion and the onset of depression, the contributions of age, pre-existing mood symptoms,
past psychiatric history, and current medical and gynecological conditions to this risk have
yet to be systematically evaluated. In addition, most of these studies involved clinical
samples in which the effects of GnRH agonists on mood could not be separated from
symptoms of the conditions for which the GnRH agonists were prescribed (e.g.,
endometriosis and other gynecological conditions). Thus, it remains to be determined
whether estradiol withdrawal and recent onset of hypogonadism are sufficient to trigger
mood problems in otherwise healthy premenopausal women.
To further examine the effects of estradiol withdrawal and hypogonadism on mood and
behavior, we administered leuprolide acetate to healthy premenopausal volunteers with no
current or past psychiatric illness and no medical or gynecological illness with the aim of
answering the following questions: 1) Does the acute induction of hypogonadism cause
clinically significant depressive symptoms in healthy premenopausal women? 2) Are there
individual symptoms associated with hypogonadism that increase susceptibility to




Women were recruited through local advertisements or self-referred from the healthy
volunteer program of the National Institutes of Health (NIH) from November 1995 to June
2010. All healthy individuals were medication free, were not pregnant, had no significant
past or current medical illness, reported regular menstrual cycles (21–35 days in length), and
had normal physical and gynecological examinations and laboratory results (including blood
cell counts, chemistry panels, and thyroid function). The absence of current or past
psychiatric illness was confirmed by the Structured Clinical Interview for DSM-IV Axis I
Disorders (19). During a 2-month screening phase, potential participants completed a 100-
mm visual analogue self-report scale measuring the severity of four affective symptoms
(sadness, anxiety, irritability, and mood swings) to confirm the absence of symptoms across
the menstrual cycle. Women were excluded from this study if they had a past or present
psychiatric illness or showed evidence of significant menstrual cycle-related or other mood
and behavioral symptoms on the daily visual analogue rating form. The protocol was
reviewed and approved by the intramural research board of the National Institute of Mental
Health, and all women provided oral and written informed consent. All women were paid
for their participation in this protocol according to the guidelines of the NIH healthy
volunteer program.
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All participants served as healthy, asymptomatic comparison subjects in a larger program of
research involving a series of separate studies examining the effects of ovarian hormone
replacement during conditions of GnRH agonist-induced hypogonadism with and without
ovarian steroid replacement on measures of brain activation and stress physiology in women
with and without premenstrual dysphoria. The present study, however, considers only how
GnRH agonist alone affected mood and behavior in the asymptomatic comparison group.
Procedures
After a 2-month screening phase, women received the first dose of depot leuprolide acetate
(TAP Pharmaceuticals, Chicago), 3.75 mg i.m., between 3 and 6 days after the onset of
menses (i.e., the early follicular phase). The subsequent leuprolide injections were then
administered every 4 weeks for up to 3 months. One group (N=30) received leuprolide alone
for 8 weeks. To match the duration of hypogonadism treatment with that used in the
companion protocol (individuals with premenstrual dysphoria), a second group (N=42)
received leuprolide alone for 12 weeks.
Participants were seen at the NIH clinic every 2 weeks for 8 or 12 weeks. Blood samples
were obtained and symptom self-ratings were completed at each clinic visit.
Outcome Measures
To evaluate symptoms, the following assessments were obtained at baseline and during each
clinic visit: 1) self-rated score from the Beck Depression Inventory (BDI; 20), used to
measure severity of depression symptoms over the 24 hours before each visit, and 2) score
from the daily rating form (21), a 6-point Likert-type scale to assess the symptoms measured
in this study, completed nightly to obtain a composite rating for the previous 24 hours; daily
rating scores ranged from 1 (symptoms not present) to 6 (symptoms present in the extreme).
The symptoms evaluated by the daily rating form included sleep disturbance, decreased
sexual interest, avoidance of social activity, loss of enjoyment or interest, irritability or
anger, mood swings, feeling sad or depressed, feeling anxious or nervous, increased
appetite, low energy, and nighttime hot flushes. For participants who had incomplete daily
ratings for the baseline phase, we used the visual analogue scale scores, converted to a scale
from 1 to 6 units, to complete the baseline ratings.
Hormone Assays
Blood samples were obtained at each clinic visit, then centrifuged, aliquoted, and stored at
−70°C until the time of assay. For the first 27 women who participated in this study, plasma
levels of estradiol were measured by radioimmunoassay as described previously (22, 23);
levels for the remaining women were assayed by chemoluminescent analyzer (Ciba Corning
Diagnostics, Cambridge, Mass., and the NIH Department of Laboratory Medicine). All
samples obtained for each woman were assayed at the same location.
Statistical Analysis
Individuals were considered to have clinically significant depressive symptoms if their BDI
scores met or exceeded the following threshold criteria: 1) BDI scores ≥10 consistent with
mild or minor depression in general medical practice (24, 25), and 2) BDI scores ≥18
consistent with moderate to severe depression (24). The number of women meeting each of
the cutoff scores was expressed as a percentage. In those women whose BDI scores were
elevated on one visit, we also determined whether they had similarly elevated scores at the
next visit—a proxy for the DSM-IV 2-week-duration criterion. We calculated 7-day
averages from daily rating symptom scores for each week during one baseline month and for
each month of leuprolide treatment. Both BDI and daily rating form data involved repeated
Ben Dor et al. Page 3













measurements with the same woman during three hormone conditions (baseline, month 1 of
leuprolide treatment, month 2 of leuprolide, and month 3 of leuprolide for those women
receiving 3 months of treatment) at weekly intervals. We examined the pattern of change in
symptom scores across three different hormone conditions: baseline prior to leuprolide
treatment, the first month of leuprolide (characterized by an acute increase or “flare” as a
result of the initial stimulation of the ovarian axis followed by a suppression of ovarian
function and subsequent estradiol withdrawal to hypogonadal plasma levels), and the last
month of leuprolide (or last 2 months in women receiving 3 months of treatment) associated
with ovarian suppression and persistent hypogonadism. Additionally, we tested for
differences in symptom severity scores and plasma estradiol levels between the second and
third month of leuprolide in those women who received 3 months of threatment.
Repeated-measures analyses were conducted with SAS, version 9.2 (SAS Institute, Inc.,
Cary, N.C.). We used multivariate repeated-measures analysis of variance (ANOVA) for
mixed models (PROC MIXED). Separately, for each of the 10 symptom ratings and plasma
estradiol levels (both actual and log-transformed values), the predictor variable of interest,
hormone condition, was modeled as a fixed effect. The covariance patterns were structured
by two effects, condition (unstructured) and week (first-order autoregressive). We used the
Kenward and Roger method for computing the degrees of freedom for tests of fixed effects.
Because of the wide age range of participants, age was explored as a possible confounder for
each symptom rating; models explored age as both a main effect and as an interaction term
(i.e., age and hormone condition). Post hoc pairwise comparisons of least square means were
compared among hormone conditions using t tests with the Bonferroni adjustment. A two-
sided p value <0.05 was considered statistically significant.
We also calculated weekly (7-day) averages of daily rating form scores for those symptoms
that changed significantly (compared with baseline) during hypogonadism. Weekly average
daily rating form scores of 2 (indicating minimal severity of a particular symptom) or
greater were used to identify women who experienced at least minimal levels of distress
during leuprolide treatment.
Finally, we examined the relationships between plasma estradiol levels and symptom scores
in the four ratings that increased significantly during leuprolide treatment compared with
baseline (BDI scores and daily rating scores for decreased sexual interest, disturbed sleep,
and nighttime hot flushes). First, we estimated the correlation coefficients between the log-
transformed plasma estradiol levels and the symptom scores from weeks 2–12 of leuprolide
treatment (or weeks 2–8 in those women receiving only 2 months of leuprolide). Because
the raw estradiol data were skewed, we used log-transformed values. In this analysis, we
calculated the partial correlation coefficients between two variables (e.g., log estradiol and
BDI scores) with repeated observations on each variable by assuming that the repeated
observations on each variable had an autoregressive structure as described by Roy (26). The
partial correlation coefficient is a summary for all women of the correlations between the
log estradiol level and symptom score in each woman. The coefficient summarizes whether
an increase in log estradiol level in the women is associated with an increase in symptom
scores. Additionally, in the four ratings that had a significant increase during leuprolide,
separate Spearman correlations were computed to assess the following about the relationship
between plasma estradiol levels and the average symptom severity during the final month of
leuprolide treatment (presumed to reflect the effects of the longest exposure to
hypogonadism in each woman): 1) the estradiol levels measured 2 weeks after the initial
injection of leuprolide (i.e., during the flare), 2) the degree of estradiol withdrawal to which
each woman was exposed from the high estradiol levels to the state of hypogonadism (i.e.,
the difference in estradiol levels between week 2 and week 4 of leuprolide treatment), and 3)
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the levels of estradiol during hypogonadism (the average level of estradiol during the final 4
weeks of leuprolide treatment).
Spearman correlation coefficients were also used to examine possible relationships between
the severity of symptoms (i.e., statistically significant changes during leuprolide treatment
compared with baseline) and the symptoms of sadness, anxiety, and irritability.
Results
Participant Characteristics
In total, 72 women ages 19–52 (mean=33 years, SD=8) participated in the study. Eight
women were older than 45. Eighteen participants were African American (25%), and three
(4%) were Asian. The mean body mass index of the participants was 24.5 (SD=4.8), and six
women (8.3%) were smokers. Participants’ parity ranged from zero to four children.
Symptom Ratings
Table 1 and Figures 1 and 2 detail the results of our symptom measurements.
BDI—Only one woman (1.3%) had a BDI score ≥18 during leuprolide treatment. In total,
four women (5.6%) had BDI scores ≥10 during leuprolide treatment, but symptoms
persisted for more than 2 weeks in only one individual. Overall, the occurrence of BDI
scores ≥10 was distributed across each of the months of leuprolide treatment, and therefore
symptoms did not cluster during any specific hormonal state. During months 2–3 of
leuprolide treatment, however, BDI scores were significantly higher than at baseline (least
squares mean=1.5, SE=0.2, and least squares mean=0.8, SE=0.2, respectively) (main effect
of hormone condition: F=3.5, df=2, 154, p<0.03; Bonferroni-corrected t=2.6, df=155,
p<0.03). In contrast, no significant differences in BDI scores were observed between month
1 and months 2–3 of leuprolide treatment or between baseline and month 1. Finally, in those
women who received 3 months of leuprolide treatment, no differences in BDI scores were
observed between month 3 and month 2 of treatment.
Daily rating form—Comparing measures during baseline with those taken during
leuprolide-induced ovarian suppression, repeated-measures ANOVA identified significant
main hormone condition effects for only three symptoms: decreased sexual interest (F=12.9,
df=2, 155, p<0.0001), disturbed sleep (F=20.2, df=2, 162, p<0.0001), and nighttime hot
flushes (F=52.3, df=2, 111, p<0.0001). Post hoc testing revealed that severity scores for all
three symptoms rose significantly from baseline levels to the second and third months of
leuprolide treatment. No differences were observed in the severity of nighttime hot flushes,
disturbed sleep, and decreased sexual interest between baseline and the first month of
leuprolide treatment. Finally, the severity of decreased sexual interest (but not nighttime hot
flushes or disturbed sleep) was significantly greater during month 3 of leuprolide treatment
compared with month 2 (Table 1). The proportion of women reporting weekly average
severity scores ≥2 (minimal severity or greater) during leuprolide treatment was 75% (44/59
women) for nighttime hot flushes, 33% (24/72 women) for decreased sexual interest, and
47% (34/72 women) for disturbed sleep.
Additional analysis—For BDI and daily symptom ratings, we explored models that
included age as both a main effect and as an interaction term with hormone condition, and, if
the interaction was not significant, age alone in a separate ANOVA. In all symptoms, both
the main and interactive effects of age were not significant, and therefore age was not a
confounder of BDI and daily rating form symptom scores.
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Symptom-hormone correlations—The partial correlation coefficients between log
estradiol levels and symptom scores were as follows: −0.1 for BDI score, −0.2 for nighttime
hot flushes, −0.08 for disturbed sleep, and −0.06 for decreased sexual interest. Therefore, as
log estradiol levels decreased, we observed a slight increase in symptom scores. No p value
was associated with these correlations; however, the magnitude of the correlations suggests
only a slight association between serial plasma estradiol levels and corresponding symptom
scores, which is consistent with the results of the overall study. The correlations with plasma
estradiol levels should be interpreted with caution given the limitations of the estradiol assay
to accurately measure plasma estradiol near the lower limits of quantitation for the assay.
Spearman correlation coefficients indicated no significant relationships between BDI scores
or severity of disturbed sleep, decreased sexual interest, or nighttime hot flushes and plasma
levels of estradiol during the final month of leuprolide treatment, plasma levels at week 2 of
leuprolide, or the change in plasma level between weeks 2 and 4 of leuprolide treatment (r
values, −0.2 to 0.1).
Symptom-symptom correlations—During the final month of leuprolide treatment,
significant correlations were found between nighttime hot flushes and disturbed sleep (r=0.5,
p<0.01) but not between severity scores for decreased sexual interest and disturbed sleep.
Severity scores for sadness, anxiety, and irritability during leuprolide treatment were not
correlated with any other symptom scores.
Discussion
It has been generally assumed that ovarian suppression and estrogen withdrawal adversely
affect mood—a causal train of events that our findings in this study do not support, at least
in healthy premenopausal women. Our results demonstrate that healthy premenopausal
women rarely exhibit negative mood symptoms during medically induced hypogonadism or
estrogen withdrawal. More importantly, these findings challenge the proposal that declining
ovarian steroid secretion alone triggers the onset of depression during the menopause
transition.
We induced hypogonadism in 72 healthy premenopausal women for 2–3 months. Yet,
despite the definitive withdrawal of ovarian steroid secretion and the fact that most
participants experienced accompanying nighttime hot flushes, disturbed sleep, and decreased
libido, only four (5.6%) experienced significant alterations in mood. These findings are
consistent with those of both Bloch et al. (27) and Owens et al. (28), who reported the
absence of significant mood changes after GnRH agonist treatment. Against these findings,
several other clinic-based studies reported that GnRH agonist-induced ovarian suppression
was associated with depression that was sufficiently severe in some women to warrant
antidepressant medication (13–17, 29). Depressive symptoms associated with GnRH agonist
ovarian suppression could reflect the effects of ovarian suppression in women who are more
vulnerable to the development of depression or who are currently depressed. Our study
could not evaluate this possibility because women with past or current mood disorders were
excluded.
During the menopause transition, up to 75% of women experience hot flushes and up to
60% experience insomnia; a smaller percentage experience a decrease in libido (30, 31). Our
study revealed significant increases in severity of nighttime hot flushes, disturbed sleep, and
decreased libido. These symptoms were reported to be of at least minimal severity and at
frequencies similar to those reported by women undergoing menopause naturally (30–35).
The fact that many of our participants complained of typical menopausal symptoms in the
absence of depression during induced hypogonadism, moreover, would seem to rule these
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symptoms out, at least in the short term, as presumed triggers for the development of
depressive symptoms.
Epidemiological studies have suggested that the menopause transition and early
postmenopause are times of increased risk for the onset of depression in some women (1–6).
However, these studies have also demonstrated that most women experience no significant
symptoms of depression during the menopause transition. Our study recapitulates one
component (loss of ovarian steroid secretion) but certainly not all of the multiple endocrine
and somatic events that accompany aging and the normal menopause transition. Consistent
with epidemiological data in perimenopausal women, our findings suggest that neither
estradiol withdrawal nor menopausal symptoms are sufficient to induce depressive
symptoms in healthy premenopausal women. Indeed, several studies have demonstrated the
relative independence of hot flushes and mood disturbances (7, 11, 12, 36, 37). Despite
limitations, our study challenges hypotheses suggesting that estrogen withdrawal, nighttime
hot flushes, or disturbed sleep alone can trigger depression during the perimenopause.
Nonetheless, the discrepancies between data collected from gynecological clinic-based
samples and data from our study (and from Owens et al. [28]) emphasize, once again (38,
39), that the effects of ovarian steroids on the brain are not uniform across individuals.
Our study has several limitations that restrict the extension of our findings to older women
transitioning through menopause and to those receiving GnRH agonists. First, we included
healthy premenopausal women with no current or past medical, gynecological, or
psychiatric illness. While these sample characteristics increase the internal validity of our
study, they decrease the generalizability of our findings to many women in the menopause
transition who, for example, could have a past history of depression. Second, the endocrine
events of the menopause transition are far more complex, and in some women more
prolonged, than simply suppressed ovarian steroid hormone secretion for 2–3 months. Thus,
inasmuch as our sample consisted of premenopausal women, our study replicated neither the
context of brain aging characteristics of most women during the natural transition to
menopause nor the extent of hormonal changes at this stage of life. Third, in our study, too
few women developed depression to examine whether or not depression occurs with
nighttime hot flushes that are more severe. Moreover, since our study measured only
nighttime hot flushes, we were limited to evaluating the impact of nighttime hot flushes on
mood, and we therefore cannot speculate about the potential negative effects of daytime hot
flushes on mood symptoms in our sample. Finally, a more accurate relationship between
plasma estradiol levels and symptoms would have been possible had we employed more
sensitive and accurate measures of estradiol using gas or liquid chromatography and mass
spectroscopic techniques.
Our data suggest that normal medical, gynecological, and psychiatric health mitigates the
risk of depression during hypogonadism. As other studies of reproductive-related mood
disorders show, the precipitation of depression secondary to reproductive hormone
manipulation requires a preexisting context of susceptibility as well as the endocrine trigger.
The fact that our results stand in marked contrast to numerous case reports of clinically
significant depression during GnRH agonist-induced hypogonadism suggests that other
factors need to be studied as potential causes for developing depression in the context of
estradiol withdrawal and the onset of hypogonadism. Trials that explore the impact of
specific risk factors for depression in women receiving GnRH agonists to treat
endometriosis or other gynecological illnesses, moreover, may shed new light on risk factors
for depression accompanying ovarian failure or hypogonadism.
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FIGURE 1. Beck Depression Inventory (BDI) Scores in 72 Women Before and After Leuprolide-
Induced Ovarian Suppression
a Significant increases in BDI scores were observed during months 2–3 of leuprolide
treatment compared with baseline scores (F=3.5, df=2, 154, p=0.03; Bonferroni-corrected
t=2.6, df=155, p<0.03), but not when compared with month 1 of leuprolide treatment. One
of the 72 women (1.3%) had a BDI score ≥18 after 6 weeks of leuprolide treatment; the
symptoms did not persist for 2 consecutive weeks. Four women overall (5.6%) had BDI
scores ≥10, and in only one woman did symptoms persist for 2 consecutive weeks (i.e., two
visits).
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FIGURE 2. Effects of Leuprolide-Induced Ovarian Suppression on Mood and Behaviora
a Histograms represent the weekly 7-day means of the symptom rating scale scores for each
month of baseline and leuprolide treatment (error bars indicate standard error of the mean).
Higher scores reflect greater symptom severity. Leuprolide-induced ovarian suppression was
accompanied by significantly decreased sexual interest (F=12.9, df=2, 155, p<0.0001),
disturbed sleep (F=20.2, df=2, 162, p<0.0001) and increased nighttime hot flushes (F=52.3,
df=2, 111, p<0.0001) compared with baseline. In contrast, no significant changes were
observed in depression or any other mood or behavioral symptoms measured. We did not
observe significant correlations between baseline plasma levels of estradiol (or the changes
in plasma levels between week 2 and week 4 of leuprolide treatment [i.e., during flare]) and
the severity of any symptom measured (depression, decreased sexual interest, nighttime hot
flushes, and disturbed sleep).
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